Raj Chakraborty, Hematologist, Oncologist, Clinical Researcher at Herbert Irving Comprehensive Cancer Center, and Assistant Professor at Columbia University Irving Medical Center, shared a post on X:
“MajesTEC-9 with both PFS and OS benefit of Teclistamab monotherapy versus PVD/Kd (in a population 100% Dara and Len-exposed)!
We finally will have a great (non-CAR T) option for relapse post frontline Dara-(V)Rd, especially in patients relapsing on continuous Dara-R! Will there be a plateau similar to MajesTEC-3?”
You can also Read: MajesTEC-3 trial: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
